This company has been acquired
Deciphera Pharmaceuticals (DCPH) Stock Overview
A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DCPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Deciphera Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.59 |
| 52 Week High | US$25.61 |
| 52 Week Low | US$9.90 |
| Beta | 0.18 |
| 1 Month Change | 0.91% |
| 3 Month Change | 60.14% |
| 1 Year Change | 76.48% |
| 3 Year Change | -28.68% |
| 5 Year Change | 6.71% |
| Change since IPO | 44.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| DCPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.08% | 1.2% | 1.6% |
| 1Y | 76.5% | 35.1% | 28.2% |
Return vs Industry: DCPH exceeded the US Biotechs industry which returned 6.8% over the past year.
Return vs Market: DCPH exceeded the US Market which returned 20.8% over the past year.
Price Volatility
| DCPH volatility | |
|---|---|
| DCPH Average Weekly Movement | 20.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DCPH's share price has been volatile over the past 3 months.
Volatility Over Time: DCPH's weekly volatility has increased from 12% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 355 | Steve Hoerter | www.deciphera.com |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.
Deciphera Pharmaceuticals, Inc. Fundamentals Summary
| DCPH fundamental statistics | |
|---|---|
| Market cap | US$2.21b |
| Earnings (TTM) | -US$190.42m |
| Revenue (TTM) | US$174.91m |
Is DCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCPH income statement (TTM) | |
|---|---|
| Revenue | US$174.91m |
| Cost of Revenue | US$242.52m |
| Gross Profit | -US$67.61m |
| Other Expenses | US$122.80m |
| Earnings | -US$190.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.20 |
| Gross Margin | -38.66% |
| Net Profit Margin | -108.87% |
| Debt/Equity Ratio | 0% |
How did DCPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/11 15:01 |
| End of Day Share Price | 2024/06/11 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Deciphera Pharmaceuticals, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |